Discover how genetic profiles and ancestry may influence the underlying neuropathology and diagnostic accuracy of ...
"Alzheimer's disease impacts too many people, more than breast cancer and prostate cancer combined." ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an ...
Disorders of Consciousness (DOC) result from focal to global brain injuries. They present a crucial challenge to neurologists and neurorehabilitation ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...
Tech Times on MSN
Tau therapy slows Alzheimer's decline in first human trial as AAIC 2026 wraps in London
Alzheimer's treatment 2026 reached an inflection point at AAIC 2026 in London: diranersen showed the first tau-targeting ...
This piece explains how researchers measured Americans' engagement in public life using multimode surveys, address-based ...
When it comes to statistics, we usually expect to be informed about what happens "on average." But sometimes the key ...
Background/Aims Retinopathy of prematurity (ROP) zone classification guides disease severity assessment and Early Treatment ...
Background In situ simulation (ISS) has seen broad use in academic emergency medicine (EM). Studies with limited clinical ...
This article aims to review existing research on the knowledge, attitude, and practice (KAP) of Chinese nurses toward ...
Introduction Stroke remains a leading cause of disability and mortality worldwide, with an urgent need for novel therapeutic strategies to improve recovery. Bupropion hydrochloride, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results